Takeda Korea receives MFDS approval for Nesina for type 2 diabetes

Published: 2013-06-05 06:59:00

Updated: 2013-06-05 06:59:00

Takeda Korea Monday announced that the Ministry of Food and Drug Safety (MFDS) has approved Nesina (alogliptin) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

People with type 2 diabetes are either resistant to insulin or do not produce enough insulin, resulti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK